title: The use of androgens in anaemia resistant to erythropoietin and i.v. iron in patients with heart and renal failure.
authors.forename: Donald
authors.initials: D
authors.lastname: Silverberg
authors.forename: Dov
authors.initials: D
authors.lastname: Wexler
authors.forename: Miriam
authors.initials: M
authors.lastname: Blum
authors.forename: Doron
authors.initials: D
authors.lastname: Schwartz
authors.forename: Adrian
authors.initials: A
authors.lastname: Iaina
mesh_terms: D000368:Aged; D000740:Anemia / Q000150:complications / Q000188:drug therapy*; D005260:Female; D005290:Ferric Compounds / Q000008:administration & dosage*; D000077605:Ferric Oxide, Saccharated; D005937:Glucaric Acid; D006333:Heart Failure / Q000150:complications*; D006801:Humans; D007275:Injections, Intravenous; D007676:Kidney Failure, Chronic / Q000150:complications*; D008297:Male; D009277:Nandrolone / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D000077603:Nandrolone Decanoate; D013395:Sucrose / Q000008:administration & dosage*
chemical_list: D005290:Ferric Compounds; D013395:Sucrose; D009277:Nandrolone; D000077605:Ferric Oxide, Saccharated; D000077603:Nandrolone Decanoate; D005937:Glucaric Acid